Supreme Court takes up drug company dispute

March 31, 2014

The Supreme Court is wading into a patent dispute between rival pharmaceutical companies over a multiple sclerosis treatment.

The justices agreed Monday to hear an appeal from Teva Pharmaceutical Industries Ltd., which claims the U.S. Court of Appeals for the Federal Circuit wrongly overturned five of its patents for the drug Copaxone.

The appeals court ruling would allow rivals Mylan Inc., Momenta Pharmaceuticals Inc. and Sandoz, Inc., to start selling generic versions of the drug later this year, after the remaining patents on the drug expire.

A had earlier ruled in Teva's favor and upheld the patents. Teva says the Federal Circuit should have deferred to factual findings made in the district court.

The justices will hear the case in the fall.

Explore further: Pfizer settles Protonix patent case for $2.15B

Related Stories

Teva says US is investigating Copaxone marketing

February 10, 2014

Teva Pharmaceutical Industries said Monday the federal government is investigating its marketing of its multiple sclerosis drug Copaxone and Parkinson's disease treatment Azilect.

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.